![Marc Voigt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 351 850 $ al 30/09/2026
Mr. Marc Voigt is a Chairman-Supervisory Board & President at Immutep SAS, a Chief Executive Officer & Executive Director at Immutep Ltd., a Co-Managing Director at Immutep GmbH and a Member at Pharma-Lizenz-Club Deutschland.
He is on the Board of Directors at Immutep Ltd. Mr. Voigt was previously employed as a Vice Chairman-Supervisory Board by Elanix Biotechnologies AG, a MD, Chief Operating & Financial Officer by caprotec bioanalytics GmbH, a Chief Financial Officer by Revotar Biopharmaceuticals AG, a Director-Executive Board by Allianz SE, a Principal by Allianz Versicherungs AG, a Director-Finance, Legal & Business Development by Medical Enzymes AG, and a General Manager-European Operations by Immutep GmbH.
He received his MBA from Freie Universität Berlin.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMUTEP LTD 1,01 % | 18/03/2026 | 14.877.395 ( 1,01 % ) | 351 850 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMUTEP LIMITED | Director Ejecutivo | 09/07/2014 |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
Immutep SAS
 Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Presidente | 18/11/2015 |
Immutep GmbH
 Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Director Ejecutivo | - |
| Empresas | Cargo | Fin |
|---|---|---|
Medical Enzymes AG
 Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Director Financiero/CFO | 02/01/2006 |
Revotar Biopharmaceuticals AG
 Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Director Financiero/CFO | 02/01/2006 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Corporate Officer/Principal | - |
| ELANIX BIOTECHNOLOGIES AG | Director/Miembro de la Junta | - |
caprotec bioanalytics GmbH
 caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Director Financiero/CFO | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 11 |
|---|---|
Allianz SE
 Allianz SE Multi-Line InsuranceFinance Provides property, casualty, life and health insurance & asset management services | Finance |
Immutep Ltd.
 Immutep Ltd. BiotechnologyHealth Technology Engages in the development of anti-cancer therapeutics | Health Technology |
Elanix Biotechnologies AG
 Elanix Biotechnologies AG BiotechnologyHealth Technology Develops and commercializes products for acute wound care, dermatological, and gynecological applications | Health Technology |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Health Technology |
Allianz Versicherungs AG
 Allianz Versicherungs AG Multi-Line InsuranceFinance Provides motor, property, liability and accident insurance services | Finance |
Freie Universität Berlin
 Freie Universität Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Health Technology |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Health Services |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Health Technology |
Pharma-Lizenz-Club Deutschland | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
